

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

**STATE BOARD OF HEALTH**  
**OKLAHOMA STATE DEPARTMENT OF HEALTH**  
**123 Robert S. Kerr**  
**Oklahoma City, Oklahoma 73102**

21  
22  
23  
24  
25  
26  
27  
28

**I. Call to Order**

Charles Grim called the meeting to order on Friday, February 11, 2022, at 10:12 a.m.

**II. Roll Call and Confirmation of a Quorum**

Board members present: Charles Grim, Jenny Alexopoulos, Jeffrey Lim, Ronald Osterhout, Bruce Storms, Kinion Whittington, Travis Wolff and Randy Grellner

Board members absent: Murali Krishna

Central staff present: Keith Reed, Interim Commissioner of Health; John Clark, Rulemaking Coordinator; Felicia Hunt, Executive Assistant; Bianca Moore, Executive Assistant; Jackie Shawnee, Chief of Staff; Adria Berry, Director, OMMA; Buffy Heater, Chief Strategy & Business Performance Officer; Dr. Gitanjali Pai, Chief Medical Officer; and Baylee Williams who served as recording secretary

**III. Review, Discussion and Approval of Minutes for the August 13, 2021, Regular Meeting**

Mr. Osterhout moved board approval of the August 13, 2021 minutes as presented. Second Dr. Storms. Motion carried.

Aye: Grim, Lim, Osterhout, Storms, Whittington, Wolff

Absent: Krishna

Abstain: Alexopoulos, Grellner

**IV. Updates & Discussion on Pandemic Response** – Keith Reed, *Interim Commissioner of Health*

Interim Commissioner Reed provided an update of the current COVID-19 cases noting a precipitous drop. He discussed the challenges of communicating data that is retrospective in nature and said the pandemic is moving toward an endemic state. Mr. Reed added the agency will be moving toward weekly reporting based off of event dates. Mr. Reed concluded his presentation with an update on the availability of Monoclonal and Antiviral Treatments available in the state noting national distribution is based on a population matrix.

**V. Updates & Responses on COVID-19 Treatments** – Dr. Gitanjali Pai, *Chief Medical Officer*

Dr. Pai provided an extensive presentation including the origin of the omicron, SARS-COV-2 Variants, Therapeutics, and Therapeutic Activity. She discussed Amubarvimab/Romlusevimab (BRII-196/BRII-198) non-competing SARS CoV-2 monoclonal neutralizing antibodies (mAB) derived from convalesced COVID-19 patients, effectiveness, safety and efficacy rates. She highlighted the use of polyclonal antibodies, SAB-185 a multi-faceted therapeutic developed to address virus mutation. Dr. Pai went on to discuss post-acute effects of COVID-19 and its persistence throughout the human body and brain. She discussed cannabinoids potential to block cellular entry of SARS-COV-2 and emerging variants but said recent small lab studies have been contradictory to one another and will need well designed clinical trials to determine

1 efficacy. Dr. Pai concluded her presentation with a review of a potential “super” vaccine that  
2 would be effective for the entire coronavirus family, essentially making it variant proof.

3 *See Attachment A*  
4

5 **VI. Presentation & Discussion on Oklahoma Medical Marijuana Authority (OMMA)** – Adria  
6 Berry, *Director, OMMA* noted that since start date on August 30, 2021 OMMA has increased  
7 staffing levels by eight percent, including several compliance inspectors. She said there are  
8 more licensed medical marijuana business in Oklahoma than any other medical marijuana  
9 program. OMMA is currently focused on regulating the industry and working with stake holders  
10 including medical professionals. Ms. Berry noted OMMA’s pillar to protect public safety and  
11 health of Oklahomans. She discussed an investigation into a grow facility that sold marijuana  
12 products to a dispensary with false Certificates of Analysis. Ms. Berry emphasized the  
13 importance of knowing where products come from when making any purchases for  
14 consumption. Members discussed needed improvements to the medical marijuana program,  
15 ways to advocate for changes and discussed the new seed to sale tracking system, METRC.  
16

17 Ms. Berry went on to discuss challenges facing the agency stating this industry has been treated  
18 with kid gloves since the beginning. She said OMMA is working with the legislature to ensure  
19 the industry stakeholders are all on the same playing field treated equally. Ms. Berry provided a  
20 high-level overview of the excise tax paid at the dispensary and the amounts going to state and  
21 local governments to include the Oklahoma School Building Fund, Oklahoma Department of  
22 Mental Health and Substance Abuse Services, Oklahoma Bureau of Narcotics, Office of  
23 Juvenile Affairs and the Tax Commission. She concluded her presentation noting the possibility  
24 of OMMA to split from OSDH and moving to the Connors Building where they will have more  
25 room to expand. Interim Commissioner Reed noted the neutrality of OSDH and expressed his  
26 willingness to partner with OMMA in whatever capacity they need to ensure they have the  
27 support to regulate the industry for the betterment of all Oklahomans.  
28

29 **VII. Presentation & Discussion on Agency Transformation** – Buffy Heater, *Chief Strategy &*  
30 *Business Performance Officer* provided an overview of recent agency transformation efforts  
31 sharing background information on how the agency got to where we are and highlighted the  
32 current landscape of transformation initiatives. Since 2021 the agency has created a bold new  
33 vision and strategy, redesigned the leadership organization structure, redesigned procurement  
34 processes, announced employee experience initiatives and stood up accountability and tracking  
35 mechanisms to achieve key milestones. Ms. Heater reviewed twenty-seven strategic initiatives  
36 to address priorities and discussed current initiative sponsors and owners. In conclusion Ms.  
37 Heater highlighted several big wins for the agency.  
38

39 **VIII. Review, Discussion & Approval of Proposed 2022 Board of Health Regular Meeting**  
40 **Schedule** – Dr. Storms moved board approval of the 2022 Board of Health regular meeting  
41 schedule as presented. Second Mr. Osterhout. Motion carried.  
42

43 Aye: Grim, Alexopoulos, Lim, Osterhout, Storms, Whittington, Wolff, Grellner  
44 Absent: Krishna  
45

46 **IX. New Business**

1 No new business.

2

3 **X. Adjournment**

4

5 Dr. Wolff moved board approval to adjourn. Osterhout provided a second. Motion carried.

6

7 Aye: Grim, Alexopoulos, Lim, Osterhout, Storms, Whittington, Wolff, Grellner

8 Absent: Krishna

9

10 The meeting adjourned at 12:06 p.m.

DRAFT